Clinical Trials in Oncology

Jacob Fleming Conferences16-17 September 2010, Budapest, Hungary.
Cancer is the fastest growing healthcare priority within the pharmaceutical industry worldwide, with rising research, treatment and commercial importance. Carefully designed and efficiently conducted clinical trial can deliver new oncology drugs and diagnostics to the marketplace. There is a number of challenges in this area which remain; specifically regarding patient recruitment and regulatory issues.

Attend to explore effective patient recruitment and enrollment strategies and understand regulatory considerations surrounding clinical trials in oncology. Leading Pharma companies will share first hand experience with adaptive trial designs and case studies on conducting clinical trials in emerging markets in CEE, APAC and India.

At this conference, you will have the chance to meet true market leaders, top speakers and real experts from the pharmaceutical industry as well as from the oncology-focused institutions and organizations. Do not miss the opportunity to gain new knowledge and join us at this event of the year.

Key speakers:

  • Vice President, Chief Clinical Officer, Teva, Israel
  • Global Clinical Operations Head Oncology, Johnson & Johnson, UK
  • Chief Medical Officer, Kiadis Pharma, The Netherlands
  • Group Head Clinical Project Management, Pfizer, Germany
  • Clinical Trials Consultant to MHRA, UK
  • Clinical Trial Head, Novartis, Switzerland
  • CRUK Professor of Translational Cancer Research, University of Glasgow, UK
  • Director Clinical Research Internal Medicine Early Stage Development, Merck Sharp & Dohme, The Netherlands
  • Principal Clinical Development Scientist, GlaxoSmithKline, UK
  • Executive Director, Oncology Global Development and Medical Affairs, Bristol Myers Squibb, France
  • Group Leader Global Clinical Development Unit Oncology, MerckSerono, Germany

Key topics:

  • Recruitment and enrollment in clinical trials. Expectations and reality.
  • Current regulatory situation in relation to clinical trials in the EU
  • Biomarkers as valuable decision making tools in clinical drug development
  • How are Pharma companies implementing and managing adaptive clinical trial
  • Challenges and opportunities of conducting clinical trials in Emerging Markets

Who should attend:
Vice presidents, Global heads, Heads, Directors, Senior managers, Managers within pharmaceutical companies and oncology-focused institutions and organizations responsible for: Oncology, Clinical research and Development, Clinical trials, Clinical operations, Medical affairs, Drug development and research, Biomarkers, Imaging.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/clinical-trials-in-oncology

About the Jacob Fleming Conferences
Jacob Fleming Conferences have always been carefully designed to provide key strategic business information and the best networking opportunities for the participants. This young, dynamically growing company provides events for specialized industries including Finance, Life Science, Telecommunications, Chemical, and cross industry sectors. Extensive research, targeted speaker selection and top class venues provide a unique incentive and exceptional opportunities for the executives and experts participating in Jacob Fleming conferences. For more information, visit www.jacobfleming.com.

Most Popular Now

Top 20 breaking World Pharma News of 2018

World Pharma News proudly presents the top 20 most popular breaking news from 2018. Have a wonderful 2019 New(s) Year filled with health, happiness, and spectacular succe...

FDA approves first treatment for rare blood diseas…

The U.S. Food and Drug Administration today approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adu...

Bristol-Myers Squibb to acquire Celgene to create …

Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristo...

Lynparza meets primary endpoint in Phase III SOLO-…

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, contro...

Pediatric leukemia 'super drug' could be developed…

Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published ...

Researchers uncover new mechanism of gene regulati…

Genes contain all the information needed for the functioning of cells, tissues, and organs in our body. Gene expression, meaning when and how are the genes being read and...

Tumors backfire on chemotherapy

Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of t...

AstraZeneca announces organisational changes

AstraZeneca is today announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a...

Sandoz and Pear Therapeutics announce US launch of…

Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD). reSET-...

Stopping cancer from recruiting immune system doub…

Cancerous tumors trick myeloid cells, an important part of the immune system, into perceiving them as a damaged part of the body; the tumors actually put myeloid cells to...

Boehringer Ingelheim initiates a collaborative par…

Science 37, an industry leader in virtual clinical trials, and Boehringer Ingelheim announced a technology enterprise collaboration agreement that will support Boehringer...

Pfizer initiates phase 2b/3 clinical trial for PF-…

Pfizer Inc. (NYSE: PFE) announced the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to s...